Heart Failure Therapy - Pharmacology

1. A patient is admitted to the cardiac ICU with acute decompensated heart failure. Examination reveals a blood pressure of 85/55 mmHg, a cardiac index of 1.8 L/min/m², cool extremities, and significant pulmonary congestion on chest x-ray. This hemodynamic profile is classified as 'cold and wet.' What is the most appropriate initial combination of intravenous therapies?
   Answer: A loop diuretic and an inotrope like milrinone. This patient presents with both congestion ('wet,' indicated by pulmonary congestion) and hypoperfusion ('cold,' indicated by hypotension, low cardiac index, and cool extremities). Management must address both problems. A loop diuretic is needed to relieve congestion. An inotrope (e.g., milrinone or dobutamine) is required to improve contractility, cardiac output, and tissue perfusion. Vasodilators are contraindicated due to the hypotension, and IV beta-blockers are contraindicated in acute decompensation with hypoperfusion.
2. A patient with HFrEF on an ACE inhibitor is transitioned to an ARNI (sacubitril/valsartan). The valsartan component provides angiotensin II receptor blockade. What is the primary beneficial mechanism of action contributed by the sacubitril component?
   Answer: Inhibition of neprilysin, leading to increased levels of beneficial natriuretic peptides. Sacubitril is a prodrug that is converted to an active metabolite which inhibits the enzyme neprilysin. Neprilysin is responsible for the breakdown of several endogenous vasoactive peptides, including natriuretic peptides (ANP, BNP), bradykinin, and adrenomedullin. By inhibiting neprilysin, sacubitril increases the levels of these peptides, which promote vasodilation, natriuresis, and diuresis, and inhibit pathologic remodeling, counteracting the neurohormonal activation seen in heart failure.
3. A 65-year-old male was recently diagnosed with HFrEF and started on carvedilol 3.125 mg twice daily. At his two-week follow-up, he reports feeling more fatigued and lightheaded, but has no orthopnea or edema. His BP is 105/65 mmHg and HR is 70 bpm. What is the most appropriate management step regarding his beta-blocker therapy?
   Answer: Continue the current carvedilol dose and reassure the patient that these symptoms often improve. Initial titration of beta-blockers in heart failure often causes transient symptoms of fatigue, dizziness, and worsening of heart failure due to their negative inotropic and chronotropic effects. The guiding principle is 'start low, go slow.' As long as the patient is hemodynamically stable and not overtly fluid overloaded, the best course of action is to continue the current low dose and allow the patient to acclimate. These side effects often subside over 2-4 weeks, after which cautious dose uptitration can be re-attempted. Discontinuation would remove a life-saving therapy.
4. A 70-year-old male with HFrEF being treated with spironolactone 25 mg daily develops tender, painful gynecomastia. His potassium and renal function are stable. The clinical team wishes to continue mineralocorticoid receptor antagonist therapy due to its mortality benefit. Which is the most appropriate therapeutic modification?
   Answer: Discontinue spironolactone and begin eplerenone. Spironolactone is a non-selective mineralocorticoid receptor antagonist that also has affinity for androgen and progesterone receptors, leading to endocrine side effects like gynecomastia and impotence. Eplerenone is a selective MRA with much lower affinity for these other steroid receptors. Switching from spironolactone to eplerenone is the standard approach to mitigate these side effects while maintaining the mortality benefit of MRA therapy. Amiloride is not an MRA and lacks the same evidence in HFrEF.
5. A physician is initiating beta-blocker therapy for a patient with newly diagnosed HFrEF. Guideline-directed medical therapy recommends using one of three specific beta-blockers that have been proven to reduce mortality in this population. Which of the following agents is NOT one of these evidence-based options?
   Answer: Atenolol Only three beta-blockers have been robustly proven in large clinical trials to reduce mortality in patients with HFrEF: carvedilol (a non-selective beta and alpha-1 blocker), metoprolol succinate (a long-acting beta-1 selective blocker), and bisoprolol (a beta-1 selective blocker). Atenolol, despite being a beta-1 selective blocker, lacks the evidence base for mortality reduction in HFrEF and should not be used for this indication. The use of metoprolol tartrate (short-acting) is also not supported by the same level of evidence as the succinate formulation.
6. An 82-year-old male with HFrEF, atrial fibrillation, and chronic kidney disease is maintained on digoxin 0.125 mg daily, carvedilol, and furosemide. He is hospitalized for a urinary tract infection and started on trimethoprim-sulfamethoxazole. Two days later, he develops confusion, nausea, and bradycardia with a heart rate of 48 bpm. An ECG shows a junctional escape rhythm. These new findings are most likely the result of:
   Answer: A pharmacokinetic drug interaction increasing digoxin levels. The patient is exhibiting classic signs of digoxin toxicity (nausea, confusion, bradycardia). Trimethoprim is a known inhibitor of the renal organic cation transporter 2 (OCT2), which is responsible for the tubular secretion of digoxin. By inhibiting this transporter, trimethoprim can significantly increase serum digoxin concentrations, leading to toxicity. While hypokalemia and worsening renal function can also contribute, the acute onset after starting a known interacting antibiotic makes this the most likely primary cause.
7. A 72-year-old female with a history of hypertension and type 2 diabetes presents with exertional dyspnea. An echocardiogram reveals an LVEF of 60%, left ventricular hypertrophy, and Grade II diastolic dysfunction, consistent with heart failure with preserved ejection fraction (HFpEF). Which medication has demonstrated a reduction in the composite outcome of cardiovascular death or hospitalization for heart failure across the full spectrum of LVEF, including HFpEF?
   Answer: Dapagliflozin SGLT2 inhibitors, such as dapagliflozin and empagliflozin, are the first class of drugs to show a consistent benefit in reducing cardiovascular death or heart failure hospitalizations in patients with HFpEF (e.g., in the DELIVER and EMPEROR-Preserved trials). While other agents are used to manage symptoms and comorbidities, SGLT2 inhibitors are now considered foundational therapy for HFpEF based on robust clinical trial evidence. Sacubitril/valsartan and spironolactone trials in HFpEF had more equivocal results, and beta-blockers have not shown a mortality benefit in this population.
8. A 67-year-old male with HFrEF (LVEF 30%) is currently managed on lisinopril 20 mg daily. Despite this, he remains symptomatic (NYHA Class II). The decision is made to switch him to sacubitril/valsartan. Which of the following represents the most critical instruction for the patient to ensure a safe transition?
   Answer: Discontinue lisinopril and begin sacubitril/valsartan 24/26 mg twice daily after a 36-hour washout period. Concurrent use of an ACE inhibitor (like lisinopril) and a neprilysin inhibitor (sacubitril) significantly increases the risk of life-threatening angioedema. This is because both ACE and neprilysin are involved in the breakdown of bradykinin. A mandatory 36-hour washout period after stopping the ACE inhibitor is required before initiating sacubitril/valsartan to allow for clearance of the ACE inhibitor and reduction of this risk. Starting concurrently or without an adequate washout period is a serious medication error.
9. A patient with HFrEF is transitioned from enalapril to sacubitril/valsartan. Before the switch, their B-type natriuretic peptide (BNP) level was 900 pg/mL. Four weeks after initiating the ARNI, the patient's symptoms have improved, but a repeat lab test shows a BNP level of 1500 pg/mL. What is the correct interpretation of this finding?
   Answer: The sacubitril component inhibits the breakdown of BNP, causing an expected rise in its measured level. Sacubitril inhibits neprilysin, an enzyme that degrades BNP. Therefore, treatment with sacubitril/valsartan leads to a predictable and expected increase in BNP levels. This elevation reflects the drug's mechanism of action, not a worsening of the patient's clinical status. For monitoring disease activity in patients on an ARNI, NT-proBNP is the preferred biomarker, as its levels are not affected by neprilysin inhibition and will decrease with effective therapy.
10. A 58-year-old female with HFrEF is being evaluated for initiation of sacubitril/valsartan. Which finding in her medical history represents an absolute contraindication to this therapy?
    Answer: History of angioedema while taking ramipril. A history of angioedema related to previous ACE inhibitor or ARB therapy is an absolute contraindication to using an ARNI (sacubitril/valsartan). The risk of developing angioedema is unacceptably high due to the combined effects on bradykinin metabolism. While hypotension, cough, and renal dysfunction are important considerations that may require dose adjustment or cautious initiation, they are not absolute contraindications.
11. A 64-year-old patient is newly diagnosed with HFrEF (LVEF 30%) and NYHA Class II symptoms. The patient has a blood pressure of 128/76 mmHg, a heart rate of 82 bpm, an eGFR of 70 mL/min/1.73m², and a serum potassium of 4.3 mEq/L. According to current guidelines, which combination represents the optimal foundational therapy that should be initiated concurrently or in rapid sequence, as tolerated?
    Answer: An ARNI, an evidence-based beta-blocker, an MRA, and an SGLT2 inhibitor. When you encounter heart failure with reduced ejection fraction (HFrEF) questions, focus on the "fantastic four" evidence-based medications that form the cornerstone of modern guideline-directed medical therapy. Current guidelines emphasize initiating these foundational therapies concurrently or in rapid sequence to maximize survival and symptom benefits. This patient has stable HFrEF with preserved kidney function and normal potassium, making them an ideal candidate for comprehensive quadruple therapy. The correct foundational combination includes an ARNI (angiotensin receptor-neprilysin inhibitor like sacubitril/valsartan), an evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), an MRA (mineralocorticoid receptor antagonist like spironolactone), and an SGLT2 inhibitor. This represents the current standard of care based on landmark trials showing mortality reduction with each component. Option A reflects outdated therapy, focusing on symptomatic treatment (diuretic, digoxin) rather than evidence-based medications that improve survival. Option B includes ivabradine, which is reserved for patients already on optimal therapy with persistent elevated heart rate, and hydralazine/isosorbide dinitrate, primarily used when ACE inhibitors/ARBs/ARNIs are contraindicated. Option C includes a dihydropyridine calcium channel blocker, which can worsen heart failure and isn't part of guideline-directed therapy for HFrEF. Study tip: Memorize the "fantastic four" for HFrEF: ARNI (or ACE/ARB), evidence-based beta-blocker, MRA, and SGLT2 inhibitor. Modern guidelines emphasize rapid, concurrent initiation rather than sequential titration when patients can tolerate multiple medications.
12. A 70-year-old male presents with acute decompensated heart failure characterized by severe dyspnea, pulmonary rales, and jugular venous distention. His blood pressure is 150/90 mmHg, and his extremities are warm. This profile is 'warm and wet.' Which intravenous medication is the most appropriate first-line therapy to rapidly reduce both preload and afterload?
    Answer: Nitroglycerin In a 'warm and wet' ADHF presentation (i.e., congested but well-perfused), intravenous vasodilators are a primary therapy, often in combination with diuretics. Nitroglycerin is an excellent choice as it is a potent venodilator, reducing preload and pulmonary congestion, and at higher doses also reduces afterload. The patient's elevated blood pressure provides adequate hemodynamic reserve for vasodilator therapy. Inotropes like dobutamine are not needed as there is no evidence of hypoperfusion ('warm').
13. A patient with severe chronic HFrEF and an eGFR of 20 mL/min/1.73m² is admitted for acute decompensation with significant volume overload. Despite treatment with high-dose intravenous furosemide (160 mg twice daily), urine output remains poor. This phenomenon is best described as diuretic resistance. Which pharmacological strategy is most appropriate to overcome this resistance?
    Answer: Adding a thiazide-type diuretic like metolazone or chlorothiazide. Loop diuretic resistance often occurs due to compensatory hypertrophy of the distal convoluted tubule, which increases sodium reabsorption at that site, blunting the effect of the loop diuretic acting on the loop of Henle. The addition of a thiazide or thiazide-type diuretic (e.g., metolazone, chlorothiazide) blocks this distal reabsorption, leading to a synergistic diuretic effect known as sequential nephron blockade. This is the standard and most effective strategy for managing loop diuretic resistance.
14. A 60-year-old non-diabetic patient with HFrEF is started on empagliflozin. The patient asks why they are being prescribed a 'diabetes medicine.' Which statement best explains the primary mechanism for the cardiovascular benefits of SGLT2 inhibitors in heart failure patients without diabetes?
    Answer: Osmotic diuresis and natriuresis leading to plasma volume contraction and reduced cardiac preload. The benefits of SGLT2 inhibitors in heart failure are independent of their glucose-lowering effects. The primary proposed mechanism for their rapid hemodynamic benefit is through induction of osmotic diuresis and natriuresis by blocking glucose and sodium reabsorption in the proximal tubule. This leads to a reduction in plasma volume, interstitial fluid, and both cardiac preload and afterload, thereby improving cardiac function. Other pleiotropic effects exist, but this is considered a core mechanism.
15. A 66-year-old male with HFrEF and type 2 diabetes is taking empagliflozin, lisinopril, and carvedilol. Due to worsening peripheral edema, a moderate dose of furosemide is added to his regimen. The addition of furosemide to empagliflozin creates an increased risk for which specific adverse event?
    Answer: Volume depletion and orthostatic hypotension When you encounter questions about drug combinations in heart failure patients, focus on how each medication's mechanism can compound or synergize with others, particularly regarding fluid and electrolyte balance. Both empagliflozin (an SGLT2 inhibitor) and furosemide (a loop diuretic) cause significant volume loss through different mechanisms. Empagliflozin blocks glucose reabsorption in the proximal tubule, creating an osmotic diuresis that pulls sodium and water into the urine. Furosemide blocks the Na-K-2Cl transporter in the loop of Henle, preventing massive sodium reabsorption and causing potent diuresis. When combined, these complementary mechanisms dramatically increase the risk of volume depletion and subsequent orthostatic hypotension, making D correct. Let's examine why the other options are incorrect: A) Hyperkalemia is unlikely because furosemide actually causes potassium wasting, and SGLT2 inhibitors don't significantly affect potassium levels. B) Acute interstitial nephritis isn't a known interaction between these specific drugs—it's more associated with NSAIDs or certain antibiotics. C) While SGLT2 inhibitors can cause euglycemic diabetic ketoacidosis, adding furosemide doesn't specifically increase this risk compared to other potential complications. Study tip: For heart failure pharmacology questions, always consider the "stacking" effect when multiple drugs affect fluid balance. SGLT2 inhibitors + diuretics = amplified volume loss risk. Remember that beneficial drug combinations in HFrEF often require careful monitoring precisely because their complementary mechanisms can create additive adverse effects.
16. A 55-year-old patient with stable, symptomatic HFrEF (LVEF 30%) is on sacubitril/valsartan 97/103 mg BID, spironolactone 25 mg daily, and dapagliflozin 10 mg daily. Due to a blood pressure of 95/60 mmHg, he cannot tolerate an increase in his carvedilol dose of 12.5 mg BID. He is in normal sinus rhythm with a resting heart rate of 78 bpm. Which medication would be the most appropriate addition to his regimen?
    Answer: Ivabradine Ivabradine is indicated to reduce heart failure hospitalizations in patients with symptomatic HFrEF who are on a maximally tolerated dose of a beta-blocker, are in normal sinus rhythm, and have a resting heart rate of 70 bpm or greater. This patient meets all criteria: symptomatic HFrEF, on max tolerated beta-blocker (due to hypotension), in sinus rhythm, and HR > 70 bpm. Amlodipine is generally avoided in HFrEF. Digoxin is an option but ivabradine specifically targets the elevated heart rate. H-ISDN is typically added for African American patients or those intolerant to ACEi/ARB/ARNI.
17. A patient with chronic HFrEF recently required hospitalization for worsening symptoms despite being on optimal doses of an ARNI, beta-blocker, MRA, and SGLT2 inhibitor. The physician is considering adding vericiguat. What is the mechanism of action of this medication?
    Answer: It directly stimulates soluble guanylate cyclase, increasing sensitivity to endogenous nitric oxide. Vericiguat is a soluble guanylate cyclase (sGC) stimulator. In heart failure, impaired nitric oxide (NO) bioavailability leads to deficient sGC stimulation and reduced cyclic guanosine monophosphate (cGMP) generation, resulting in endothelial dysfunction. Vericiguat directly stimulates sGC and also sensitizes it to endogenous NO, increasing intracellular cGMP, which leads to smooth muscle relaxation and vasodilation. It is indicated for high-risk patients with recent worsening HF events.
18. A 68-year-old female with HFrEF (EF 35%) is on stable doses of lisinopril, carvedilol, and furosemide. Her baseline K+ is 4.2 mEq/L and eGFR is 55 mL/min/1.73m². Spironolactone 12.5 mg daily is added to her regimen. One week later, repeat labs show K+ 4.9 mEq/L and eGFR 48 mL/min/1.73m². Which is the most appropriate action?
    Answer: Continue spironolactone at the current dose and recheck labs in 2-4 weeks. A modest increase in serum potassium and a small decrease in eGFR are expected physiological effects after initiating a mineralocorticoid receptor antagonist (MRA). The current potassium level of 4.9 mEq/L is still within the acceptable range (typically <5.5 mEq/L for continuation). The most appropriate action is to continue the current dose and monitor the patient's labs to ensure they stabilize, rather than making a premature dose adjustment or discontinuing a guideline-directed therapy.
19. A patient admitted for acute decompensated heart failure becomes euvolemic after receiving a continuous infusion of intravenous furosemide totaling 80 mg over 24 hours. The patient is now ready for discharge. Given that the oral bioavailability of furosemide is approximately 50%, what would be an appropriate equivalent total daily oral dose to prescribe?
    Answer: 160 mg The conversion from intravenous to oral furosemide requires accounting for its variable and often poor oral bioavailability, which is typically estimated at 50%. Therefore, to achieve a similar systemic exposure, the oral dose should be approximately double the intravenous dose. An effective total IV dose of 80 mg would translate to an equivalent oral dose of approximately 160 mg (80 mg / 0.5 bioavailability = 160 mg). Prescribing 80 mg orally would represent a significant dose de-escalation.

Start this quiz